QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NYSEAMERICAN:IBIO

iBio (IBIO) Stock Forecast, Price & News

$0.30
0.00 (0.00%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.30
$0.32
50-Day Range
N/A
52-Week Range
$0.26
$8.75
Volume
274,349 shs
Average Volume
1.56 million shs
Market Capitalization
$5.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

iBio MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of iBio in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$31,598 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.38 out of 5 stars


IBIO stock logo

About iBio (NYSEAMERICAN:IBIO) Stock

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

IBIO Price History

IBIO Stock News Headlines

iBio Announces Amendment to Credit Agreement with Woodforest
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
iBio Inc. stock falls Tuesday, underperforms market
iBio Inc. stock rises Monday, outperforms market
Pharos IBio Co Ltd (388870)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Why Is iBio (IBIO) Stock Up 16% Today?
iBio: Q3 Earnings Insights
iBio Inc. stock rises Friday, outperforms market
See More Headlines
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Company Calendar

Last Earnings
11/15/2021
Today
9/26/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:IBIO
Previous Symbol
NASDAQ:IBIO
Employees
105
Year Founded
N/A

Profitability

Net Income
$-50,300,000.00
Pretax Margin
-11,133.67%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Book Value
$7.27 per share

Miscellaneous

Free Float
16,398,000
Market Cap
$5.06 million
Optionable
Not Optionable
Beta
-3.14
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Martin B. Brenner D.V.M. (Age 52)
    Ph.D., CEO & Chief Scientific Officer
    Comp: $578.3k
  • Mr. Robert B. Kay (Age 83)
    Interim Sec. & Interim Treasurer
    Comp: $92.69k
  • Mr. Felipe Duran (Age 43)
    Chief Financial Officer
  • Stephen Kilmer
    Investor Relations Officer
  • Mr. Marc Banjak J.D.
    Gen. Counsel
  • Ms. Lisa Middlebrook
    Chief HR Officer













IBIO Stock - Frequently Asked Questions

Should I buy or sell iBio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBIO, but not buy additional shares or sell existing shares.
View IBIO analyst ratings
or view top-rated stocks.

Are investors shorting iBio?

iBio saw a increase in short interest in August. As of August 31st, there was short interest totaling 296,700 shares, an increase of 6.1% from the August 15th total of 279,600 shares. Based on an average daily volume of 727,900 shares, the short-interest ratio is presently 0.4 days. Approximately 1.3% of the company's shares are short sold.
View iBio's Short Interest
.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($1.00) EPS for the quarter, beating analysts' consensus estimates of ($1.25) by $0.25. The biotechnology company had revenue of $0.21 million for the quarter.

When did iBio's stock split?

iBio shares reverse split before market open on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avantax Planning Partners Inc. (0.92%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Martin Brenner and Robert Matthew Lutz.
View institutional ownership trends
.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $0.30.

How much money does iBio make?

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $5.06 million and generates $2.38 million in revenue each year.

How many employees does iBio have?

The company employs 105 workers across the globe.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173.

This page (NYSEAMERICAN:IBIO) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -